# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

# FORM 8-A

FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934

# **Dermata Therapeutics, Inc.**

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation or organization)

3525 Del Mar Heights Rd., #322 San Diego, California (858) 800-2543 (Address of principal executive offices)

Securities to be registered pursuant to Section 12(b) of the Act:

 Title of each class

 to be so registered

 Common Stock, par value \$0.0001 per share

 Warrants, exercisable for one share of Common Stock

Name of each exchange on which each class is to be registered The Nasdaq Stock Market LLC The Nasdaq Stock Market LLC

If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), please check the following box.

If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), please check the following box.  $\Box$ 

If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. 🗆

Securities Act registration statement file number to which this form relates: 333-256997

Securities to be registered pursuant to Section 12(g) of the Act: None (Title of Class)

86-3218736 (I.R.S. Employer Identification No.)

> 92130 (Zip Code)

#### Item 1. Description of Registrant's Securities to be Registered.

Dermata Therapeutics, Inc. (the "*Registrant*"), hereby incorporates by reference the description of its common stock, par value \$0.0001 per share, and warrants to purchase shares of common stock to be registered hereunder contained under the heading "Description of Securities" in the Registrant's Registration Statement on Form S-1 (File No. 333-256997), as originally filed with the Securities and Exchange Commission (the "*Commission*") on June 10, 2021, as subsequently amended (the "*Registration Statement*"), and in the prospectus included in the Registration Statement to be filed separately by the Registrant with the Commission pursuant to Rule 424(b) under the Securities Act of 1933, as amended, which prospectus shall be deemed to be incorporated by reference herein.

## Item 2. Exhibits.

In accordance with the "Instructions as to Exhibits" with respect to Form8-A, no exhibits are required to be filed as part of this registration statement because no other securities of the Registrant are registered on The Nasdaq Stock Market LLC and the securities registered hereby are not being registered pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended.

## SIGNATURE

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: August 11, 2021

## DERMATA THERAPEUTICS, INC.

By: <u>/s/ Gerald T. Proehl</u> Gerald T. Proehl

Gerald T. Proehl Chief Executive Officer